N/A N=78 Evaluation of a Lifestyle Intervention for Employees With Prediabetes
Prediabetes · Overweight · Obese
Primary: Body Weight — -5.12; -0.37 kg — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=336 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
Chronic Kidney Disease · Hyperphosphatemia
Primary: Change in Serum Phosphorus Levels From Week 12 to Week 16 (LOCF) (ITT2) — -0.24; 1.27 mg / dL
Phase 2 N=44 Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease · Lung Disease
Primary: Absolute Monocyte Count in BAL Post-LPS Challenge — 398; 514.4 x10^4 cells/mL
Phase 3 N=471 Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Primary: Cumulative Recurrent Rates of Gastric or Duodenal Ulcers — 2.8; 1.4; 21.7 Events/100 participants/24 weeks — p=<0.001
Phase 2 N=63 AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
Chronic Obstructive Pulmonary Disease · Lung Disease
Primary: Number of Participants With Clinically Significant Changes in Laboratory Variables Other Than Monocytes — 0; 0 Participants
N/A N=4 Relationship Between the Menstrual Cycle and Heart Disease in Women
Coronary Heart Disease
Primary: Total to HDL Cholesterol Ratio — 0.146; 0.148; -0.89 Total to HDL Cholesterol Ratio
Phase 3 N=239 Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)
Diabetic Macular Edema
Primary: Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12 — 8.2; 8.9; 0.3 Letters
Phase 3 N=518 Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Type 1 Diabetes Mellitus
Primary: Change From Baseline to Week 24 in HbA1c — -0.21; -0.29; -0.40 Percent of hemoglobin
N/A N=40 Visual Performance Investigation of Two Toric Soft Contact Lenses
Refractive Error · Astigmatism · Myopia
Primary: Mean Ocular Coma Score at 5mm Pupil at Day 30 — 0.16; 0.24 micrometers
Phase 3 N=103 A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants With a Sustained Response — 36; 63 percentage of participants — p=0.004
N/A N=62,335 European Active Surveillance Study for Intrauterine Devices
Uterine Perforation
Primary: Uterine Perforation Rate — 61; 20 participants
N/A N=10 Volume Kinetics for Starch Solution and Acetated Ringers
Blood Volume · Blood Coagulation
Primary: Volume Effects for Hydroxyethyl Starch, Ringer's Solution or a Combination of Both. — 5.53; 2.94; 3.12; 4 Litre
Phase 4 N=1,250 Jet Injection for Influenza
Influenza, Human
Primary: Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT) — 4.43; 4.38; 5.64; 5.64 Titers
Phase 4 N=13 Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
Chronic Constipation
Primary: The Number of High-Amplitude Propagating Contractions (HAPC) — 8.7; 2.9 Number of HAPC with amplitude ≥100mmHg — p=0.012
Phase 2 N=45 Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Overall Response Rate (Complete Response + Partial Response) at the End of Cycles 3 and 6 Using the 2007 International Working Group Criteria — 71; 82 percentage of…